Researchers at Stanford have developed prodrug derivatives of protein kinase C (PKC) modulators that have lower toxicity and are more effective than the parent compound. PKC modulators are being developed to treat a variety of diseases.
Researchers at Stanford have developed a method of preventing Graft versus Host Disease (GVHD) by inhibiting a specific immune receptor. GVHD is a major debilitating complication of transplantation.
Stanford researchers at the Xing Lab have developed a novel technique to enable retrospective tuning of soft tissue contrast in MRI (i.e. adjusting the contrast after the image acquisition) using a deep learning-based strategy.
Researchers at Stanford have developed humanized therapeutic antibodies to treat cancers, particularly melanoma, inflammatory disorders such as sarcoidosis and skin and organ fibrosis.
Stanford researchers have developed a new method and medical device to close the abdominal wall fascia after laparotomy to reduce the incidence of incisional hernias. Incisional hernias occur in nearly 50% of high risk patients leading to costs of about $3B annually.
An interdisciplinary team of Stanford engineers have developed a low-cost, patented, in situ method to efficiently produce electricity from organic matter such as wastewater.
Stanford researchers have discovered that dietary metabolites, specifically alpha-ketoglutarate, are able to delay retinal degeneration to treat blinding retinal diseases regardless of the type of retinal condition.
Stanford researchers have developed a hydrodynamic treadmill system for a tracking microscope that allows long term observations of biological and abiotic systems over large length and time scales.